Evidence tier: B — investigational (positive Phase 3 topline; not yet approved for hair loss).
Here's why this one has the hair-loss world paying attention: clascoterone is the first genuinely new topical mechanism to reach late-stage trials in years. It goes after the same enemy as finasteride — DHT — but from a completely different angle, and without swallowing a pill that acts on your whole body.
Let me break down what it actually is, what the trials really show, and where it stands right now.
What clascoterone is
Clascoterone is a topical androgen-receptor inhibitor. In hair loss it's being developed under the name Breezula (the same molecule is already FDA-approved as Winlevi for acne — a useful sign its basic safety is reasonably understood).
You apply it to the scalp. That's the pitch in one line: an anti-androgen you rub on, not one you swallow.
How it works (and why that matters)
Androgenetic alopecia is driven by DHT binding to androgen receptors in genetically sensitive follicles, which slowly miniaturizes them. There are three ways to interrupt that:
- Make less DHT (finasteride, dutasteride — the 5-alpha reductase inhibitors).
- Lower DHT locally at the scalp.
- Block the receptor so DHT can't bind — which is what clascoterone does.
Think of it like this. Finasteride turns down the supply of DHT across your entire body. Clascoterone leaves the supply alone and instead puts a cover over the lock — the androgen receptor — right where you apply it, on the scalp. Because it's topical and broken down quickly into an inactive form, very little acts systemically.
Here's the problem it's trying to solve: a lot of people either can't tolerate finasteride's potential systemic (including sexual) side effects, or are simply unwilling to risk them. A local, receptor-level anti-androgen is aimed squarely at that group. That — not a bigger regrowth number — is clascoterone's real story.
What the trials actually show
Clascoterone 5% solution has been through Phase 3 trials for male androgenetic alopecia, and the topline results were positive: a statistically significant improvement in target-area hair count versus placebo, with 12-month data suggesting benefits were sustained on continued use. [1][2][3]
Now — read that the way we taught you to read trial results on the pipeline tracker:
- You'll see a big relative improvement figure quoted versus placebo. Impressive-sounding relative numbers usually translate to a more modest real-world density gain — think meaningful, not miraculous. Judge it by absolute hair-count gains and photos, not the percentage.
- The 12-month data reportedly showed continued gains on treatment, and a drop-off when patients switched to placebo — i.e. like every AGA treatment, it works while you use it. [3]
- Reported side effects have been broadly similar to the vehicle (the inactive base), with minimal systemic exposure — consistent with the "local, not systemic" design. [2]
Bottom line on the data: genuinely promising, mechanistically novel, late-stage — but still topline/investigational until the full peer-reviewed results and an FDA decision are in.
Where it stands in 2026
As of writing, clascoterone for hair loss is not FDA-approved — it's approved only for acne (as Winlevi). The developer has signaled regulatory submissions, with a US filing for the hair-loss indication pointed at roughly early 2027. [2][4] Timelines slip, so treat any date as provisional. We update this page as status changes.
Realistic expectations (if it's ever an option for you)
- It's shaping up as a topical anti-androgen — most interesting to people avoiding oral finasteride/dutasteride, or wanting to add a scalp-level DHT block to a growth stimulant like minoxidil.
- It is not a magic wand and, like everything in AGA, appears to require ongoing use to keep the benefit.
- Whether it beats or complements existing options is exactly the kind of question for a dermatologist once (if) it's approved — not something to conclude from a press release.
How I'd track it (my two cents)
If clascoterone lands and I tried it, here's how I'd avoid fooling myself: baseline crown and hairline photos before starting, then the same shots — same angle, distance, and light — every month. AGA moves slowly and the mind edits memories generously. I built the progress tracker precisely so a new treatment's effect is measured, not felt. That's the only way you'll know if a novel drug is earning its place in your regimen.
FAQ
Is clascoterone available for hair loss yet? No. As of mid-2026 it's investigational for hair loss (Phase 3, positive topline) and FDA-approved only for acne. A hair-loss filing has been signaled for around early 2027. [2][4]
Is clascoterone better than finasteride? Different mechanism, not proven "better." Finasteride reduces DHT systemically with strong long-term data; clascoterone blocks the receptor locally with minimal systemic exposure, which mainly appeals to those avoiding oral anti-androgens. There's no head-to-head verdict — and this isn't medical advice.
Does clascoterone have side effects like finasteride? Its whole design is to minimize systemic exposure, and trial side effects were reportedly close to the inactive vehicle. That's encouraging but not a guarantee; full long-term data and approval will tell the real story. [2]
What's the difference between clascoterone and Breezula and Winlevi? Same active molecule. Winlevi is the approved acne product; Breezula is the hair-loss development name; clascoterone is the drug itself.
Sources
- Dermatology Times — Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results. https://www.dermatologytimes.com/view/clascoterone-5-delivers-strong-phase-3-hair-growth-results
- Dermatology Times — Cosmo Pharmaceuticals Reports Positive 12-Month Safety Data for Clascoterone 5% in Male AGA. https://www.dermatologytimes.com/view/cosmo-pharmaceuticals-reports-positive-12-month-safety-data-for-clascoterone-5-in-male-aga
- The Dermatology Digest — Top-line Phase 3 Data: Clascoterone 5% Solution Performs Well in Male Hair Loss. https://thedermdigest.com/topline-phase-3-data-clascoterone-5-solution-performs-well-in-male-hair-loss/
- Cosmo Pharmaceuticals — Phase III 12-Month Data for Clascoterone (company release). https://www.cosmohealthconfidence.com/news/98958067-clascoterone-12-month-safety-results-ende
Investigational drug; not medical advice. See our editorial standards and medical disclaimer. Verify every source before republishing, and refresh this page when the peer-reviewed results or FDA decision land.